Phillips-Cremins Research Identifies Protein Involved in Brain Development

Phillips-Cremins
Jennifer Phillips-Cremins, Ph.D.

The vast majority of genetic mutations that are associated with disease occur at sites in the genome that aren’t genes. These sequences of DNA don’t code for proteins themselves, but provide an additional layer of instructions that determine if and when particular genes are expressed. Researchers are only beginning to understand how the non-coding regions of the genome influence gene expression and might be disrupted in disease.

​​​​​​​​​​​​Jennifer Phillips-Cremins, assistant professor in the Department of Bioengineering in the University of Pennsylvania’s School of Engineering and Applied Science, studies the three-dimensional folding of the genome and the role it plays in brain development. When a stretch of DNA folds, it creates a higher-order structure called a looping interaction, or “loop.” In doing so, it brings non-coding sites into physical contact with their target genes, precisely regulating gene expression in space and time during development.

Phillips-Cremins and lab member Jonathan Beagan have led a new study identifying a new protein that connects loops in embryonic stem cells as they begin to differentiate into types of neurons. Though the study was conducted in mice, these findings inform aspects of human brain development, including how the genetic material folds in the 3-D nucleus and is reconfigured as stem cells become specialized. Better understanding of these mechanisms may be relevant to a wide range of neurodevelopmental disorders.

Cremins lab members Michael Duong, Katelyn Titus, Linda Zhou, Zhendong Cao, Jingjing Ma, Caroline Lachanski and Daniel Gillis also contributed to the study, which was published in the journal Genome Research.​​​​​​

Continue reading at the SEAS blog.

New Faculty: Interview With Konrad Kording

Kording
Konrad Kording, PhD

This week, we present our interview with incoming faculty member Konrad Kording, who starts as a Penn Integrates Knowledge Professor in the Department of Bioengineering and the Department of Neuroscience in the Perelman School of Medicine. Konrad and Andrew Mathis discuss what neuroscience is and isn’t, the “C” word (consciousness), and what it’s like for a native of Germany to live in the United States.

 

Tsourkas Joint Venture Featured in “Inquirer”

Tsourkas
Andrew Tsourkas, Ph.D.

Andrew Tsourkas, Ph.D., who is an associate professor in the Department of Bioengineering, cofounded PolyAurum LLC, a company using gold particles to develop technologies to improve cancer therapies, in 2015. Dr. Tsourkas founded the company with two faculty members from the Perelman School of Medicine: Jay Dorsey, M.D., Ph.D., and Dave Cormode, Ph.D., the latter of whom is also a secondary factory member in BE. The name PolyAurum combines the word polymer with aurum, the Latin word for “gold.” Gold has been found to be able to enhance the effects of radiation therapy in cancer without damaging healthy tissue.

Dr. Tsourkas’s work with his colleagues at PolyAurum was featured recently in the The Philadelphia Inquirer. Debra Travers, the CEO of PolyAurum and herself a cancer survivor, was interviewed by the newspaper for its business section.

According to the article, Drs. Tsourkas and Cormode

have worked to make gold more biocompatible, resulting in PolyAurum’s current technology, Dorsey said. The gold nanocrystals are contained in a biodegradable polymer that allows enough metal to collect in a tumor. The polymer then breaks down, releasing the gold for excretion from the body so that it does not build up in key organs.

Read more at the Inquirer Web site.

New Faculty: Interview With Lukasz Bugaj

Bugaj
Lukasz Bugaj, Ph.D.

This week, we present our interview with incoming faculty member Lukasz Bugaj, who starts as an assistant professor at Penn BE in January. Lukasz and Andrew Mathis discuss tennis and crew, Lukasz’s subfield of optogenetics, and life as the child of a statistician.

Please note: This was our first interview recorded by telephone. We will try to improve the quality of the audio, but for now, be advised that the questions are at a far lower volume than the responses, so set your volume, accordingly, particularly if you are listening on headphones.

Burdick Recognized by NIH in Two Programs

Burdick
Jason Burdick, Ph.D.

Jason Burdick, Ph.D., professor in the Department of Bioengineering, was among the recent recipients of a grant from Sharing Partnership for Innovative Research in Translation (SPIRiT), a pilot grant program awarded by the Clinical and Translational Science Award (CTSA) division of the National Institutes of Health (NIH).

Dr. Burdick’s research, undertaken with Albert Sinusas, MD, of Yale, concerns the development of a noninvasive treatment to limit the damage to the heart caused by heart attacks, which are suffered annually by almost 750,000 Americans. Using single-photo emission computed tomography (SPECT), the technique identifies the damaged heart muscle on the basis of enzymes activated by damage, followed by the targeted administration of bioengineered hydrogels for the delivery of therapeutics

Dr. Burdick says, “This research has the potential to advance treatments for the many individuals with heart attacks who have few current options. Our approach uses injectable materials and advanced imaging techniques to address the changes in protease levels after heart attacks that can lead to tissue damage.”

In other news, Dr. Burdick was one of 12 researchers named by the NIH’s Center for Engineering Complex Tissues to lead collaborative projects aimed at generating complex tissues for several parts of the body.

Organ-on-a-Chip Earns Big CRI Grant for Huh Lab

CRI grant Huh
Dan Huh, Ph.D.

As we reported earlier, Dan Huh, Wilf Family Term Chair & Assistant Professor in the Department of Bioengineering, has been awarded a $1 million grant from the Cancer Research Institute (CRI), along with its first CRI Technology Impact Award.

Recently, the Penn Engineering Blog featured a story on Dr. Huh’s grant and the research it will support for the next three years. You can read the story at the SEAS blog.

Congratulations again to Dr. Huh!

New Faculty: Interview With Mike Mitchell

Mitchell
Mike Mitchell, Ph.D.

Here’s the promised interview with new faculty member Mike Mitchell, who starts as assistant professor of bioengineering at Penn in the Spring 2017 semester. Mike and editor Andrew E. Mathis discuss Mike’s background and education, where cancer research is now and where it’s heading, and just how big the radius is on the cheesesteak zone of impact around Philadelphia.

Enjoy!

Uncertainty Investigated by Neuroscience

uncertainty

 

Uncertainty is part of life, but the underlying neuroscience of how we make decisions under conditions of uncertainty is only beginning to be understood. In a paper published Monday by Nature Human Behaviour, new Penn Bioengineering faculty member and Penn Integrates Knowledge Professor Konrad Kording, Ph.D., and his coauthor, Iris Vilares, Ph.D., of University College London, offer additional evidence that dopamine lies at the heart of how the brain operates when there is a lack of certainty.

Drs. Kording and Vilares devised a simple computerized test that examined the extent to which test takers relied on previous knowledge vs. what they saw at the present moment. They then administered the test to a cohort of patients with Parkinson’s disease, a condition associated with depleted dopamine levels. The patients were tested both while taking dopaminergic medication and while off it. They found that dopaminergic medication caused the patients to pay greater attention to sensory (i.e., visual) information — an effect that diminished as the patients learned. Ultimately, the study provided evidence that dopamine levels were related to the tendency to rely on new information, also called likelihood uncertainty.

“Scientists believe that understanding uncertainty is key to understanding how the brain computes,” Dr. Kording says. “There are many theories in this space. We provide fairly clean evidence for one of them, which is that dopamine encodes likelihood uncertainty. This information could change the way people think about the manner in which the brain deals with uncertainty.”

Macrophages Engineered Against Cancer Cells

macrophages Discher
Dennis Discher, Ph.D.

Dennis E. Discher, Ph.D., Robert D. Bent Professor in the Department of Chemical and Biomolecular Engineering and a secondary faculty member in the Department of Bioengineering, was the lead author on a recent study that showed that engineered macrophages (a type of immune cell) could be injected into mice, circulate through their bodies, and invade solid tumors in the mice, engulfing human cancers cells in the tumors.

According to Cory Alvey, a graduate student in pharmacology who works in Professor Discher’s lab and the first author on the paper, said, “Combined with cancer-specific targeting antibodies, these engineered macrophages swarm into solid tumors and rapidly drive regression of human tumors without any measurable toxicity.”

Read more here.

Mind Control and an Ethical Appeal

mind control brain
A “wiring diagram of the human brain,” produced using diffusion MRI scans of the brain.

A group of four scholars from the University of Pennsylvania, including Bioengineering professor Danielle Bassett, have issued a call in the journal Nature Human Behaviour for greater safeguards for patients as treatments in the field of neuroscience evolve and come ever closer to resembling “mind control.”

“While we don’t believe,” Bassett said, “that the science-fiction idea of mind control, totally overriding a person’s autonomy, will ever be possible, new brain-focused therapies are becoming more specific, targeted and effective at manipulating individuals’ mental states. As these techniques and technologies mature, we need systems in place to make sure they are applied such that they maximize beneficial effects and minimize unwanted side effects.”

Read more at the Penn News Web Site.